Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline

Wierman, Margaret E.; Basson, Rosemary; Davis, Susan Ruth; Khosla, Sundeep; Miller, Karen K.; Rosner, William; Santoro, Nanette

doi:10.1210/jc.2006-1121

Cited by 274 publications

(174 citation statements)

References 130 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…As TT and bioactive testosterone are very low in women, there is controversy regarding the best methods to accurately measure androgens. This study used high-affinity antibodies and radioactive labels along with an extraction step, which is reported to provide a more accurate detection of low concentrations of testosterone (40). The lower limit of quantification for the testosterone assay was 0.15 ng/ml and in this study all women exceeded this value.…”

Section: Obesitymentioning

confidence: 82%

Androgenic sex steroids contribute to metabolic risk beyond intra‐abdominal fat in overweight/obese black and white women

Perry

Wang

Goldberg

et al. 2013

Obesity

View full text Add to dashboard Cite

Objective: To determine the independent contribution of androgenic sex hormones beyond visceral adipose tissue (VAT) on metabolic risk. Design and Methods: A cross-sectional evaluation of 66 (36 white and 30 black) premenopausal overweight/obese women using multiple regression analyses to determine the independent effects of sex hormone-binding globulin (SHBG), total testosterone (TT), and free testosterone using the free androgen index (FAI) on metabolic variables above VAT. Results: SHBG contributed to the variance in insulin (P ¼ 0.003), insulin resistance using HOMA-IR (P ¼ 0.006), and high-density lipoprotein cholesterol 2 (P ¼ 0.029). TT contributed to the variance in systolic and diastolic blood pressure (P < 0.001), total cholesterol (P ¼ 0.003), low-density lipoprotein cholesterol (P ¼ 0.003), and apolipoprotein B (P ¼ 0.004). FAI contributed to the variance in the greatest number of metabolic variables beyond VAT. There was also a significant race-FAI interaction for fasting glucose (P ¼ 0.013). A Pearson's correlation coefficient showed a significant relationship between FAI and glucose in white women (r ¼ 0.48, P ¼ 0.003) while showing no relationship in black women (r ¼ À0.01, P ¼ 0.941). Conclusions: Our study showed that androgenic sex steroids contributed significantly to the variance in metabolic variables associated with health risk. However, they do not provide sufficient information relevant to glucose status in black women.

show abstract

Section: Obesitymentioning

confidence: 82%

Androgenic sex steroids contribute to metabolic risk beyond intra‐abdominal fat in overweight/obese black and white women

Perry

Wang

Goldberg

et al. 2013

Obesity

View full text Add to dashboard Cite

show abstract

“…Blood samples were not collected during the same day of the menstrual cycle for pre-menopausal women and samples were obtained only once. Further, the assays used to measure hormone levels may not be as sensitive and specific as newly developed assays such as sequential mass spectrometry [41]. To attempt to minimize the daily and monthly variability of hormone levels, samples were collected between 8 and 10 AM after an overnight fast, and statistical analyses were adjusted for body mass index and number of days since the beginning of the last menstrual period.…”

Section: Discussionmentioning

confidence: 99%

Genetic polymorphisms, hormone levels, and hot flashes in midlife women

et al. 2007

View full text Add to dashboard Cite

Objective-Hot flashes disrupt the lives of millions of women each year. Although hot flashes are a public health concern, little is known about risk factors that predispose women to hot flashes. Thus, the objective of this study was to examine whether sex steroid hormone levels and genetic polymorphisms in hormone biosynthesis and degradation enzymes are associated with the risk of hot flashes.Methods-In a cross-sectional study design, midlife women aged 45 to 54 years (n=639) were recruited from Baltimore and its surrounding counties. Participants completed a questionnaire and donated a blood sample for steroid hormone analysis and genotyping. The associations between genetic polymorphisms and hormone levels, as well as the associations between genetic polymorphisms, hormone levels, and hot flashes were examined using statistical models.Results-A polymorphism in CYP1B1 was associated with lower dehydroepiandrosterone-sulfate (DHEA-S) and progesterone levels, while a polymorphism in CYP19 (aromatase) was associated with higher testosterone and DHEA-S levels. Lower progesterone and sex hormone binding globulin levels, lower free estradiol index, and a higher ratio of total androgens to total estrogens were associated with the experiencing of hot flashes. A polymorphism in CYP1B1 and a polymorphism in 3βHSD were both associated with hot flashes.Conclusion-Some genetic polymorphisms may be associated with altered levels of hormones in midlife women. Further, selected genetic polymorphisms and altered hormone levels may be associated with the risk of hot flashes in midlife women.

show abstract

“…5,[15][16][17] These findings have raised questions regarding the safety of testosterone administration to postmenopausal women. 18 However, reverse associations between testosterone and markers of atherosclerosis have been reported as well. 19,20 This review aims to summarize the current evidence on the role of endogenous testosterone in cardiovascular health in postmenopausal women and to highlight potential adverse effects of testosterone therapy.…”

Section: Introductionmentioning

confidence: 99%

Testosterone, SHBG and cardiovascular health in postmenopausal women

Brand

Schouw

2010

Int J Impot Res

View full text Add to dashboard Cite

Cardiovascular disease (CVD) affects men and women differently with women having a lower incidence and later onset of disease. Research has recently refocused interest on the cardiovascular role of androgens. The purpose of this review is to summarize the evidence available on the association between testosterone and cardiovascular health in postmenopausal women. Published studies relating testosterone and sex hormone-binding globulin (SHBG) to CVD and its risk factors were reviewed. Studies included in this review suggest that increased androgenicity, characterized by high testosterone and low SHBG levels, is associated with an adverse CVD risk factor profile in postmenopausal women. However, evidence for an association with cardiovascular events is lacking and it is uncertain whether the observed associations with endogenous testosterone have clinical implications regarding the use of postmenopausal testosterone therapy. Large-scale, longitudinal studies relating testosterone and SHBG levels to cardiovascular risk factors and endpoints are needed to determine the temporal relationship between androgenicity and cardiovascular risk and to ascertain the long-term efficacy and safety of testosterone therapy in postmenopausal women.

show abstract

Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline

Cited by 274 publications

References 130 publications

Androgenic sex steroids contribute to metabolic risk beyond intra‐abdominal fat in overweight/obese black and white women

Androgenic sex steroids contribute to metabolic risk beyond intra‐abdominal fat in overweight/obese black and white women

Genetic polymorphisms, hormone levels, and hot flashes in midlife women

Testosterone, SHBG and cardiovascular health in postmenopausal women

Contact Info

Product

Resources

About